Actively Recruiting
A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies
Led by Xinqiao Hospital of Chongqing · Updated on 2025-07-14
120
Participants Needed
1
Research Sites
124 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this study, we collected the data of immunohistochemistry, gene detection, image, OS, PFS, Orr, and so on. Secondly, the database of immunotherapy for malignant tumor was established, and the predictive model was constructed to verify and establish the rationality and validity of the biomarkers and predictive system of immunotherapy
CONDITIONS
Official Title
A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent and ability to follow the study protocol
- Diagnosed with advanced malignant solid tumors such as non-small-cell lung carcinoma, stomach, breast, or urinary system cancer confirmed by histopathology
- Cancer stage IV according to the eighth edition of IASLC
- Performance status (PS) between 0 and 2 with expected survival over 3 months
- Age between 18 and 75 years
- No contraindications to treatment with immune checkpoint inhibitors
You will not qualify if you...
- Poor compliance violating study rules
- Severe dysfunction of vital organs including heart, liver, or kidneys
- Presence of other malignant tumors
- Investigator's judgment that participation is not suitable for the patient
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the second affiliated hospital of Army medical university
Chongqing, Chongqing Municipality, China, 40037
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here